메뉴 건너뛰기




Volumn 36, Issue 1, 2017, Pages 2-8

Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study

Author keywords

Down syndrome; immune deficiency; neuromuscular disease; palivizumab; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

EID: 84988640967     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001340     Document Type: Article
Times cited : (26)

References (29)
  • 1
    • 84855717861 scopus 로고    scopus 로고
    • Epidemiology of respiratory syncytial virus infection in preterm infants
    • Resch B, Kurath S, Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J. 2011;5:135-143.
    • (2011) Open Microbiol J , vol.5 , pp. 135-143
    • Resch, B.1    Kurath, S.2    Manzoni, P.3
  • 2
    • 84960077836 scopus 로고    scopus 로고
    • Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics
    • Respiratory Syncytial Virus Network (ReSViNET)
    • Mazur NI, Martinón-Torres F, Baraldi E, et al; Respiratory Syncytial Virus Network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3:888-900.
    • (2015) Lancet Respir Med , vol.3 , pp. 888-900
    • Mazur, N.I.1    Martinón-Torres, F.2    Baraldi, E.3
  • 3
    • 84905228480 scopus 로고    scopus 로고
    • Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
    • Committee on infectious diseases and bronchiolitis guidelines committee
    • Committee on infectious diseases and bronchiolitis guidelines committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620-638.
    • (2014) Pediatrics , vol.134 , pp. e620-e638
  • 4
    • 84925234244 scopus 로고    scopus 로고
    • Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants
    • Baraldi E, Lanari M, Manzoni P, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65.
    • (2014) Ital J Pediatr , vol.40 , pp. 65
    • Baraldi, E.1    Lanari, M.2    Manzoni, P.3
  • 5
    • 84930751431 scopus 로고    scopus 로고
    • Update of recommendations on the use of palivizumab as prophylaxis in RSV infections
    • Comité de Estándares de la SENeo
    • FiguerasAloy J, CarbonellEstrany X; Comité de Estándares de la SENeo. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. AnPediatr (Barc). 2015;82:199.e1-2.
    • (2015) AnPediatr (Barc) , vol.82 , pp. 199e1-199e2
    • FiguerasAloy, J.1    CarbonellEstrany, X.2
  • 6
    • 84941628695 scopus 로고    scopus 로고
    • Preventing hospitalizations for respiratory syncytial virus infection
    • Canadian Paediatric Society, Infectious Diseases and Immunization Committee
    • Robinson JL, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015;20:321-333.
    • (2015) Paediatr Child Health , vol.20 , pp. 321-333
    • Robinson, J.L.1    Le Saux, N.2
  • 7
    • 84861470949 scopus 로고    scopus 로고
    • High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: A dilemma of specific prevention
    • Manzoni P, Paes B, Resch B, et al. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev. 2012;88(suppl 2):S34-S41.
    • (2012) Early Hum Dev , vol.88 , pp. S34-S41
    • Manzoni, P.1    Paes, B.2    Resch, B.3
  • 8
    • 84860306234 scopus 로고    scopus 로고
    • Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
    • Paes B, Mitchell I, Li A, et al. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr. 2012;171:833-841.
    • (2012) Eur J Pediatr , vol.171 , pp. 833-841
    • Paes, B.1    Mitchell, I.2    Li, A.3
  • 9
    • 79960650624 scopus 로고    scopus 로고
    • CARESS: The Canadian registry of palivizumab
    • CARESS investigators
    • Mitchell I, Paes BA, Li A, et al; CARESS investigators. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30:651-655.
    • (2011) Pediatr Infect Dis J , vol.30 , pp. 651-655
    • Mitchell, I.1    Paes, B.A.2    Li, A.3
  • 10
    • 84952870921 scopus 로고    scopus 로고
    • Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
    • Italian Society of Neonatology
    • Bollani L, Baraldi E, Chirico G, et al; Italian Society of Neonatology. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97.
    • (2015) Ital J Pediatr , vol.41 , pp. 97
    • Bollani, L.1    Baraldi, E.2    Chirico, G.3
  • 11
    • 84887436227 scopus 로고    scopus 로고
    • Public Health England. Accessed January 31, 2016
    • Public Health England. Immunisation against infectious diseases. 2015. Available from: https://www.gov.uk/government/publications/respiratorysyncytial-virus-the-green-book-chapter-27a. Accessed January 31, 2016.
    • (2015) Immunisation Against Infectious Diseases
  • 12
    • 84941963037 scopus 로고    scopus 로고
    • Serious adverse events in the canadian registry of children receiving palivizumab (caress) for respiratory syncytial virus prevention
    • CARESS investigators
    • Chen JJ, Chan P, Paes B, et al; CARESS investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for respiratory syncytial virus prevention. PLoS One. 2015;10:e0134711.
    • (2015) PLoS One , vol.10 , pp. e0134711
    • Chen, J.J.1    Chan, P.2    Paes, B.3
  • 13
    • 0034619028 scopus 로고    scopus 로고
    • Adverse drug reactions: Definitions, diagnosis, and management
    • Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-1259.
    • (2000) Lancet , vol.356 , pp. 1255-1259
    • Edwards, I.R.1    Aronson, J.K.2
  • 14
    • 33745553210 scopus 로고    scopus 로고
    • Summary proceedings from the bronchopulmonary dysplasia group
    • Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006;117: S52-S56.
    • (2006) Pediatrics , vol.117 , pp. S52-S56
    • Walsh, M.C.1    Szefler, S.2    Davis, J.3
  • 15
    • 79960243558 scopus 로고    scopus 로고
    • A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease
    • Motavizumab Cardiac Study Group
    • Feltes TF, Sondheimer HM, Tulloh RM, et al; Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70:186-191.
    • (2011) Pediatr Res , vol.70 , pp. 186-191
    • Feltes, T.F.1    Sondheimer, H.M.2    Tulloh, R.M.3
  • 16
    • 84901841907 scopus 로고    scopus 로고
    • Respiratory syncytial virus prophylaxis in Down syndrome: A prospective cohort study
    • CARESS investigators
    • Yi H, Lanctôt KL, Bont L, et al; CARESS investigators. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics. 2014;133:1031-1037.
    • (2014) Pediatrics , vol.133 , pp. 1031-1037
    • Yi, H.1    Lanctôt, K.L.2    Bont, L.3
  • 17
    • 84865430737 scopus 로고    scopus 로고
    • Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children
    • Robbie GJ, Zhao L, Mondick J, et al. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927-4936.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 4927-4936
    • Robbie, G.J.1    Zhao, L.2    Mondick, J.3
  • 18
    • 84887990669 scopus 로고    scopus 로고
    • Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis
    • La Via WV, Notario GF, Yu XQ, et al. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26:666-671.
    • (2013) Pulm Pharmacol Ther , vol.26 , pp. 666-671
    • La Via, W.V.1    Notario, G.F.2    Yu, X.Q.3
  • 19
    • 16644372782 scopus 로고    scopus 로고
    • Palivizumab use in very premature infants in the neonatal intensive care unit
    • Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004;114:e554-e556.
    • (2004) Pediatrics , vol.114 , pp. e554-e556
    • Wu, S.Y.1    Bonaparte, J.2    Pyati, S.3
  • 20
    • 0031729747 scopus 로고    scopus 로고
    • Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
    • American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn
    • American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216.
    • (1998) Pediatrics , vol.102 , pp. 1211-1216
  • 21
    • 0031683919 scopus 로고    scopus 로고
    • Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    • The IMpact-RSV Study Group
    • The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
    • (1998) Pediatrics , vol.102 , pp. 531-537
  • 22
    • 84861466431 scopus 로고    scopus 로고
    • What is BPD in 2012 and what will BPD become?
    • Jobe AH. What is BPD in 2012 and what will BPD become? Early Hum Dev. 2012;88 Suppl 2:S27-S28.
    • (2012) Early Hum Dev , vol.88 , pp. S27-S28
    • Jobe, A.H.1
  • 23
    • 25144507172 scopus 로고    scopus 로고
    • Optimal timing and dosing intervals of palivizumab in premature neonates: Still some work to do
    • Manzoni P, Sala U, Gomirato G, et al. Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do. Pediatrics. 2005;115:1439-1440.
    • (2005) Pediatrics , vol.115 , pp. 1439-1440
    • Manzoni, P.1    Sala, U.2    Gomirato, G.3
  • 24
    • 0038350757 scopus 로고    scopus 로고
    • Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the Palivizumab Outcomes Registry
    • Palivizumab Outcomes Registry Study Group
    • Parnes C, Guillermin J, Habersang R, et al; Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35:484-489.
    • (2003) Pediatr Pulmonol , vol.35 , pp. 484-489
    • Parnes, C.1    Guillermin, J.2    Habersang, R.3
  • 25
    • 47149094332 scopus 로고    scopus 로고
    • Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry
    • Palivizumab Outcomes Registry Group
    • Frogel M, Nerwen C, Cohen A, et al; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28:511-517.
    • (2008) J Perinatol , vol.28 , pp. 511-517
    • Frogel, M.1    Nerwen, C.2    Cohen, A.3
  • 26
    • 85006594230 scopus 로고    scopus 로고
    • Child Health British Columbia Committee
    • Child Health British Columbia Committee. BC guidelines for RSV infection immunoprophylaxis. Available from: http://www.neonatalcann.ca/Infant%20Eligibility/British%20Columbia/BC%20RSV%20Program%20 Manual%202014-2015.pdf.
    • BC Guidelines for RSV Infection Immunoprophylaxis
  • 27
    • 71949099031 scopus 로고    scopus 로고
    • Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
    • American Academy of Pediatrics. Committee on Infectious Disease
    • American Academy of Pediatrics. Committee on Infectious Disease. Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-16701.
    • (2009) Pediatrics , vol.124 , pp. 1694-16701
  • 28
    • 84898427609 scopus 로고    scopus 로고
    • Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus
    • Makari D, Checchia PA, Devincenzo J. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Hum Vaccin Immunother. 2014;10:607-614.
    • (2014) Hum Vaccin Immunother , vol.10 , pp. 607-614
    • Makari, D.1    Checchia, P.A.2    Devincenzo, J.3
  • 29
    • 84880152109 scopus 로고    scopus 로고
    • Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries
    • Paes B, Mitchell I, Li A, et al. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol. 2013;2013:917068.
    • (2013) Clin Dev Immunol , vol.2013 , pp. 917068
    • Paes, B.1    Mitchell, I.2    Li, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.